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BioactivitiesAbstract Didemnaketals are rare terpenoid class reported only in the marine ascidian Didemnum
species. They possess important biological activities like HIV-1 protease inhibitor, protein kinase
inhibition, antimicrobial, antiproliferative, and cytotoxic. A compilation of new naturally occurring
didemnaketals reported during 1991–2014 is provided with available physical and spectral data: mp,
[a]D, UV, IR,
1H and 13C NMR as well as biological activities and references.
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70 G.A. Mohamed et al.1. Introduction
The number of natural products isolated from marine organ-
isms increases rapidly and many new compounds are discov-
ered every year.1 A large proportion of natural compounds
have been isolated from marine invertebrates such as sponges,
ascidians, bryozoans, and molluscs, and some of them are cur-
rently in clinical trials.2 Ascidians or sea-squirts are cosmopoli-
tan, exclusively marine invertebrates, which represent the most
highly evolved group of animals commonly investigated by
marine natural product chemists.3 Attention has focused on
ascidians because of their biologically active metabolites. The
chemistry of ascidians has become one of the most active ﬁelds
of marine natural products. It has been demonstrated that the-
se sea creatures are proliﬁc producers of unusual structures
with signiﬁcant bioactivities.4 The compounds isolated from
genus Didemnum are diverse and possess a wide range of bio-
logical activities such as antiplasmodial,5 antiviral,6 cytotoxic,7and protein kinase inhibitors.8 Didemnaketals are very rare
linear heptaprenoids, isolated from the marine Didemnum spe-
cies. To date, seven spiroketals, didemnaketals A–G (1–7)
(Fig. 1) were isolated from the marine Didemnum species col-
lected from different geographical locations including Aulup-
tagel Island Palau9,10and Nabq/Sharm El-Sheikh on the
Egyptian Red Sea coast.8,11 Two of them, didemnaketals A
(1) and B (2) were reported as a result of oxidation and metha-
nolysis of polar isoethonic ester, didemnaketal C (3) during
long storage of the ascidian sample in MeOH.9,10,12 While,
didemnaketals C–G (4–7) were isolated from fresh samples
of marine ascidian Didemnum species.8,9,11 Here, we listed
the didemnaketals that have appeared in the literature over
the past few decades, with their biological activities, physical
constants, spectral data, and references. For each compound
these data were listed in the following order: name; structure;
melting point (C); optical rotation (concentration, solvent);
UV (solvent, kmax nm, log e); IR (medium, absorption band
Figure 1 (continued)
Naturally occurring didemnaketals 71in cm-1); 1H NMR (spectrometer frequency, solvent, chemical
shift values in ppm, starting with H-3 and listed in order); 13C
NMR (spectrometer frequency, solvent, chemical shift in ppm
values starting with C-1 and listed in order); molecular formu-
la; calculated molecular weight; and reference(s) (Tables 1–3).
The main aim of this review is for rapid identiﬁcation of isolat-
ed didemnaketals by comparison of spectral data as well as to
draw attention of the natural product chemists for evaluation
of biological and pharmacological activities of the isolated
didemnaketals. The high-light of pharmacological activity
may possibly draw the attention of the synthetic chemists for
design of new drugs using the known didemnaketals.2. The structural features of didemnaketals
Didemnaketals are a rare class of polyisoprenoids, character-
ized by the presence of bicyclic ketal region from C-12 to C-
20 and penta-ester side chain.13,14 The linear heptaprenoid
structure contains a number of intriguing structural featuressuch as a spiroketal moiety and two side chains with eight chiral
centers.13,15 Didemnaketals D (4) and E (5) isolated from
Didemnum sp. collected from Sharm El-sheikh on the Red
Sea coast,8 differ from didemnaketal A isolated from the
magenta ascidian Didemnum sp. collected at Auluptagel island,
Palauin,10 in lacking the methyl at C-6 and the hydroxy at C-21,
as well as possessing an additional substituent at C-20. They
showed new moieties at C-6 (methyl ester in D (4) and ethyl
ester in E (5) and an oxygen functionality at C-20 (acetoxy in
D (4) and hydroxy in E (5)). The new moieties at C-20 represent
an unprecedented and complicated spiroketal/ketal (in 4) and
spiroketal/hemiketal (in 5) moieties, which are not observed
in the previously described spiroketal systems.8 Moreover,
didemnaketals F (6) and G (7) are characterized by the absence
of the methyl functionality at C-2 and terminal methyl ester
moiety of the spiroketal skeleton. Instead, they possess a termi-
nal methyl ketone moiety at the left part of the molecule. Addi-
tionally, 6 possesses a di-substituted double bond at C-2/C-3,
while 7 has a secondary alcohol at C-3. Also, they have spiroke-
tal/hemiketal functionality at the right part of the molecule.8,11
Figure 1 (continued)
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The gross structures of didemnaketals A–G (1–7) were deter-
mined by extensive 1D and 2D NMR spectroscopic ana-
lyses.8–11
The absolute stereochemistry at the stereogenic centers of
didemnaketals A–C (1–3) was determined to be 5S,6S,7R,8R,
10S,11S,12S,14S,16S,18R,20S,21S (didemnaketal A) and
5S,6S,7R,8R,10S,11S,12S,14S,16S,18R,20S,21S,26S (didem-
naketals B and C),14 using a combination of degradation and
derivatization experiments, chiral shift methods, as well as syn-
thesis of the C9–C28 subunit containing the spiroketal moiety
through a highly convergent strategy in didemnaketal B
(2).12,14 The conﬁguration of didemnaketals D and E was
assigned to be 5S,6S,7R,8R,10S,11S,12R,14S,16S,18R on the
basis of NOESY correlations and comparison of the NMR
spectral data with those of previously reported didemnake-
tals.8 Fuwa and coworkers revised Faulkner‘s stereochemical
assignment of didemnaketals B through its total synthesis.16
The stereochemical relationship of the C5/C6, C6/C7, and
C7/C8 stereogenic centers was correlated by NMR spectro-scopic analyses on suitable acetonide derivatives. X-ray crys-
tallographic analysis is used for assignment of the relative
conﬁguration of the C10-C20 spiroacetal domain. The abso-
lute conﬁguration of the C5, C8, C11, and C21 stereogenic cen-
ters was determined by application of the modiﬁed Mosher
analysis, while that of the C20 and C26 stereogenic centers
was assigned on the basis of the phenyl glycine methyl ester
(PGME) method.16 The geometry of the C2–C3 double bond
was conﬁrmed to be E by NOE experiment as well as by a large
3JH,H value (
3JH2,H3 = 16.5 Hz).
11,16 The absolute conﬁgura-
tion of didemnaketals F (6) and G (7) was determined to be
5S,6S,7R,8R,10S,11S,12S,14R,16S,18R,11 based on Fuwa‘s
stereochemical revision of didemnaketals B (2) as well as exten-
sive spectroscopic studies.16
4. Biological activities of didemnaketals
4.1. Potent HIV-1 protease inhibitor activity
Replication of human immunodeﬁciency virus (HIV) entails
expression of several viral polyproteins which require the pres-
Table 1 NMR spectroscopic data of didemnaketals A (1), D (4), and E (5).
No. Didemnaketal A (1) Didemnaketal D (4) Didemnaketal E (5)
dH (J in Hz)
a dC
a dH (J in Hz)
b dC
b dH (J in Hz)
a dC
a
1 - 168.1 - - - 176.7
2 - 130.2 - 175.3 - 131.7
3 6.71 ddd (5, 7, 2) 136.1 - 133.1 5.15 t (6.2) 127.2
4 2.49 ddd (16, 5, 5)
2.53 ddd (16, 7, 7)
30.8 5.23 t (6.0) 128.2 2.03 m 33.3
5 4.83 m 72.2 2.24 m, 2.17 m 34.6 3.45 dt (11.6, 7.1) 72.9
6 2.09 m 36.7 3.51 dt (11.5, 7.3) 75.1 2.29 dt (11.6, 6.9) 41.8
7 5.16 dd (9, 2) 72.9 3.00 m 42.2 4.85 t (9.1) 67.9
8 5.22 br t (10) 70.6 4.95 m 69.0 3.95 m 69.3
9 1.24 m, 1.61 m 32.2 4.12 m 70.9 1.64 m, 1.25 m 36.4
10 1.84 m 29.4 1.68 m, 1.23 m 37.9 1.94 m 33.7
11 4.78 dd (6, 6) 78.2 2.26 m 35.5 5.00 m 74.7
12 3.69 m 69.2 5.08 dd (6.5, 6.3) 76.8 3.67 m 73.9
13 0.81 ddd (12, 12, 12)
1.45 br d (13)
34.5 4.08 m 75.5 1.05 m, 0.80 m 36.6
14 1.93 m 24.9 1.27 m, 0.77 m 37.7 1.69 m 25.4
15 0.98 br m
1.67 dd (14, 3)
43.9 1.78 m 27.6 1.62 m, 1.08 m 45.0
16 - 98.4 1.08 m, 1.67 m 46.2 - 98.8
17 1.45 br d (13)
1.59 br d (13)
40 - 100.3 2.10 m, 1.95 m 46.7
18 1.99 m 24.3 2.22 m, 2.07 m 47.6 1.68 m 24.6
19 1.34 br dd (14, 3)
1.71 ddd (14, 11, 5)
31.8 1.75 m 25.8 2.20 m 33.9
20 3.89 ddd (11, 5, 3) 67.5 1.62 m, 1.42 m 37.7 - 99.7
21 4.14 dd (5, 5) 79.1 - 101.5 2.99 d (13.5)
2.80 d (13.5)
41.1
22 - 209.3 3.07 d (14.1)
3.05 d (14.1)
42.3 - 202.6
23 2.32 s 28.1 - 204.4 2.16 s 20.6
24 1.82 s 12.5 2.15 s 21.1 1.63 s 17.0
25 0.98 d 9.8 1.71 s 17.6 - 173.2
26 0.98 d 16.1 - 178.2 0.88 d (6.8) 14.8
27 0.86 d (7) 22.0 0.88 d (6.5) 15.1 0.92 d (6.9) 22.2
28 1.08 m 20.6 0.95 d (7.2) 22.7 0.94 d (6.5) 19.6
29 3.72 s 51.8 0.92 d (6.5) 22.5 3.65 s 51.7
30 - 173.8 3.68 s 55.3 - 170.3
31 2.28 br m 27.5 - 170.4 2.15 m 26.6
32 1.08 m 8.3 2.24 m 26.4 1.05 t (7.5) 7.7
33 - 170.2 1.02 t (6.3) 8.4 - 169.9
34 1.98 s 20.8 - 171.4 2.05 s 21.3
35 - 172.4 2.06 s 21.2 - 173.2
36 2.13 m 43.1 - 178.2 2.15 m 41.8
37 2.04 m 25.2 2.32 m 40.9 2.85 m 33.3
38 0.93 d 22.3 2.90 m 35.4 1.30 d (6.6) 14.3
39 0.93 d 22.4 1.22 d (7.0) 17.5 1.30 d (6.6) 14.3
40 - 172.7 1.22 d (7.0) 17.5 - 168.6
41 2.24 m 43.6 - 172.2 1.98 m 34.2
42 2.08 m 25.5 2.31 m 38.1 1.92 m 30.1
43 0.98 d 22.5 2.03 m 31.1 1.19 d (6.5) 17.2
44 0.98 d 22.5 0.98 (d, 7.0) 20.0 1.19 d (6.5) 17.2
45 - - 0.98 (d, 7.0) 20.0 4.15 q (6.9) 60.1
46 - - 3.67 s 51.9 1.25 t (6.9) 14.3
47 - - - 172.2 - -
a Recorded in CDCl3 at 400 and 100 MHz.
b Recorded in CD3OD at 500 and 125 MHz.
Naturally occurring didemnaketals 73ence of a virus-speciﬁc protease for their maturation. Inhibition
of this enzyme results in immature viral particles and inhibition
of viral replication in vitro. Inhibition of HIV-1 protease is oneof the most effective ways to treat AIDS, but the emergence of
drug resistant viral strains mandates new approaches.13 Didem-
naketals A (1) and B (2) were found to inhibit HIV-1 protease
Table 2 NMR data of didemnaketals B (2) and C (3) (CDCl3, 500 and 125 MHz).
No. Didemnaketal B (2) Didemnaketal C (3)
dH (J in Hz) dC dH (J in Hz) dC
1 - 168.0 - 168.0
2 - 130.3 - 130.2
3 6.69 t (7) 135.5 6.66 t (6) 135.9
4 2.47 dt (16, 7)
2.51 dt (16, 5)
30.9 2.41 m, 2.50 m 30.9
5 4.83 m 72.3 4.79 m 72.2
6 1.96 m 37.0 1.93 m 36.9
7 5.12 dd (9, 3) 72.7 5.10 t (9) 72.7
8 5.23 dd (9, 8) 70.6 5.18 m 70.5
9 1.22 m, 1.66 m 32.9 1.14, m, 1.60 m 33.0
10 1.90 m 29.5 1.90 m 29.6
11 4.77 dd (6, 5) 78.6 4.71 t (6) 78.5
12 3.85 m 69.1 3.84 m 69.0
13 0.80 q (14)
1.44 m
35.1 0.78 m, 1.40 m 35.0
14 2.06 m 24.8 2.04 m 24.4
15 1.00 d (7)
1.67 m
44.3 0.96 m 44.3
16 - 98.3 - 98.4
17 1.54 br d (14)
1.64 m
40.7 1.39 m, 1.54 m 40.6
18 1.91 m 24.5 2.05 m 24.7
19 1.12 m
1.58 br d (14)
29.98 1.07 m, 1.56 m 29.6
20 3.87 m 66.6 3.84 m 66.3
21 4.05 d (3) 78.0 4.03 br s 77.6
22 - 133.0 - 133.0
23 5.48 t (7) 126.3 5.41 t (7) 125.9
24 2.08 m, 2.08 m 24.9 1.91 m, 2.04 m 25.1
25 1.25 m, 1.38 m 36.5 1.20 m, 1.39 m 36.2
26 2.00 m, 30.04 1.90 m 29.4
27 2.13 m
2.29 dd (7, 5)
41.5 1.90 m, 2.24 m 41.7
28 - 173.5 - 173.8
29 1.84 s 12.6 1.80 m 12.6
30 0.97 d (7) 9.9 0.94 d (7) 9.9
31 0.98 d (7) 16.2 0.97 d (7) 16.1
32 0.86 d (7) 22.1 0.82 d (6) 22.1
33 1.07 d (6) 20.84 1.04 d (7) 20.8
34 1.62 s 13.3 1.57 br s 13.6
35 0.96 d (7) 19.6 0.91 d (7) 19.5
36 3.73 s 51.8 3.70 s 51.9
37 - 173.7 - 173.3
38 2.35 m, 2.35 m 27.6 2.22 m, 2.28 m 27.6
39 1.09 t (7) 8.9 1.06 t (7) 8.9
40 - 170.1 - 170.3
41 1.98 s 20.77 1.95 s 20.8
42 - 172.3 - 172.4
43 2.13 d (7) 43.2 2.12 m 43.1
44 2.06 m 25.3 2.05 m 25.2
45 0.94 d (6) 22.5 0.90 d (7) 22.5
46 0.94 d (6) 22.5 0.95 d (7) 22.5
47 - 172.7 - 172.8
48 2.25 d (7) 43.7 2.22 m 43.6
49 2.12 m 25.6 2.00 m 25.6
50 0.99 d (6) 22.6 0.90 d (7) 22.5
51 0.99 d (6) 22.6 0.95 d (7) 22.5
52 3.66 s 51.3 4.46 t (7) 59.5
53 - - 3.17 t (7) 50.0
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Table 3 NMR data of didemnaketals F (6) and G (7) (CDCl3,
600 and 150 MHz).
No. Didemnaketal F (6) Didemnaketal G (7)
dH (J in Hz) dC dH (J in Hz) dC
1 - 198.5 - 207.2
2 6.11 d (16.5) 133.0 2.61 dd (14.5, 7.3)
2.45 dd (14.5, 7.5)
50.1
3 6.75 dt (16.5, 6.8) 145.8 4.28 quin (7.3) 67.5
4 1.97 m 29.9 1.65 m, 0.87 m 36.1
5 3.45 dt (11.6, 7.3) 72.3 3.45 dt (11.5, 6.9) 72.3
6 2.30 dt (11.6, 6.9) 41.6 2.95 dt (11.6, 6.5) 41.7
7 4.83 t (9.6) 67.9 4.83 t (9.8) 67.9
8 4.30 m 67.5 3.90 m 67.5
9 1.70 m, 1.25 m 36.8 1.75 m, 1.29 m 36.9
10 1.92 m 34.1 1.95 m 33.9
11 5.02 dd (6.8, 6.3) 76.5 5.01 dd (6.5, 6.3) 76.8
12 3.86 m 75.3 3.86 m 75.3
13 1.48 m, 0.88 m 36.1 1.47 m, 0.85 m 36.1
14 1.72 m 25.5 1.70 m 26.6
15 1.62 m, 1.08 m 44.8 1.63 m, 1.08 m 44.7
16 - 98.7 - 98.7
17 1.72 m, 1.56 m 42.0 1.74 m, 1.55 m 41.1
18 1.75 m 24.6 1.75 m 24.6
19 2.15 m, 1.74 m 33.1 2.15 m 32.0
20 - 99.8 - 99.8
21 2.95 m, 2.86 m 41.2 2.85 m, 2.72 m 41.1
22 - 202.5 - 202.5
23 2.19 s 21.3 2.06 s 21.0
24 2.24 s 29.7 2.16 s 31.2
25 - 172.6 - 175.8
26 0.90 d (6.5) 14.8 0.88 d (6.5) 14.8
27 0.91 d (6.8) 22.2 0.92 d (6.8) 22.0
28 0.97 d (6.5) 19.8 0.90 d (6.5) 20.5
29 - 170.5 - 170.2
30 2.16 q (7.3) 26.6 2.18 q (7.3) 26.8
31 1.03 t (7.3) 7.5 1.03 t (6.9) 7.5
32 - 170.2 - 170.5
33 2.05 s 21.0 2.01 s 21.3
34 - 176.6 - 176.6
35 2.13 m 41.8 2.33 m 39.8
36 2.87 m 33.9 2.85 m 33.2
37 1.20 d (6.8) 17.2 1.22 d (6.8) 17.2
38 1.20 d (6.8) 17.2 1.22 d (6.8) 17.2
39 - 168.6 - 168.6
40 2.03 m 33.2 2.05 m 33.1
41 1.97 m 31.2 1.97 m 29.7
42 0.95 d (6.3) 22.0 0.93 d (6.3) 22.2
43 0.95 d (6.3) 22.0 0.93 d (6.3) 22.2
44 4.11 q (6.8) 60.4 3.64 s 51.8
45 1.27 t (6.8) 14.3
Naturally occurring didemnaketals 75with an IC50 of 2 and 10 lM, respectively.
10 So, several synthet-
ic studies of the didemnaketals especially A (1) have been con-
ducted to determine the structural components necessary for
activity; as well as stable analogs that may provide a unique
and potent mode of HIV-1 protease inhibition by an unusual
mechanism.13 Unfortunately, didemnaketal C (3) did not inhi-
bit HIV-1 in a peptidolysis assay.14,17
4.2. Protein kinase inhibitory activity
Didemnaketals D (4) and E (5) displayed moderate protein
kinase inhibitory activity against CDK5, CK1, DyrK1A and,
GSK3 at concentration 10 lg/mL. The IC50 of bothcompounds were higher than 10 lg/mL. Such activity is not
sufﬁcient to pursue with these compounds into the in vivo
studies.8
4.3. Antimicrobial activity
Didemnaketals D (4) and E (5) were evaluated for their antimi-
crobial potential against Gram-positive bacteria, Gram-nega-
tive bacteria, and yeast using the disk diffusion method.
Didemnaketal D (4) showed moderate activity (11 mm, inhibi-
tion zone) toward Staphylococcus aureus ATCC 6538, while
didemnaketal E (5) showed moderate activity (11 mm, inhibi-
tion zone) against Bacillus subtilis ATCC CC33.8 While,
didemnaketal F (6) showed strong antimicrobial activity again-
st Escherichia coli ATCC 25922 and Candida albicans ATCC
14053 with inhibition zones of 20 and 24 mm at a concentra-
tion of 100 lg/disk. Didemnaketal G (7) showed moderate
activity against C. albicans with an inhibition zone of 17 mm
at the same concentration.11
4.4. Antiproliferative and cytotoxic activities
Didemnaketals F (6) and G (7) displayed moderate antiprolif-
erative activity against HeLa cells with IC50s of 49.9 and
14.0 lM, respectively using sulforhodamine B (SRB) assay.
In contrast, cytotoxic effects were not observed with didem-
naketal F (6) at concentrations up to 50 lM compared with
paclitaxel as a positive control (IC50 of 0.0017 lM).
11
5. Spectral data
Didemnaketal A (1): Clear oil; [a]D 11.0 (c 0.8, CHCl3); IR
(CHCl3) mmax 3490, 1735, 1712 cm
1; HRFABMS m/z
825.5030 (calcd for C44H73O14, [M + H]
+, 825.5000).10
Didemnaketal B (2): Clear oil; IR (CHCl3) mmax 3500, 1735,
1710 cm1; HRFABMS m/z 933.5951 (calcd for C52H85O14,
[M  OH]+, 933.59393).10,16
Didemnaketal C (3): Colorless oil; [a]D + 48 (c 0.067,
CH2Cl2); UV (CH3CN) kmax 213 nm; IR (ﬁlm) mmax 3440,
2955, 1740, 1715 cm1; HRFABMS m/z: 1067.5522 (calcd
for C53H88O18SNa, 1067.5589).
9
Didemnaketal D (4): Colorless oil, [a]D 51.9 (c 1.5,
CHCl3); UV (MeOH) kmax (log e) 246 (4.08) nm; IR (KBr) mmax
1732, 1715, 1296, 1050 cm1; HRESIMS m/z 911.4923 (calcd
for C47H75O17, [M + H]
+, 911.4926).8
Didemnaketal E (5): Colorless oil, [a]D 46.3 (c 1.5,
CHCl3); UV (MeOH) kmax (log e) 234 (4.18) nm; IR (KBr) mmax
3495, 1735, 1710, 1291, 1056 cm1; HRESIMS m/z 883.5029
(calcd for C46H75O16, [M + H]
+, 883.5027).8
Didemnaketal F (6): Colorless oil; [a]D – 72.8 (c 1.5,
CHCl3); UV (MeOH) kmax (log e) 252 (3.93) nm; IR (ﬁlm) mmax
3460, 1735, 1720, 1675, 1650, 1070 cm1; HRESIMS m/z
853.4950 (calcd for C45H73O15 [M + H]
+, 853.4949).11
Didemnaketal G (7): Colorless oil; [a]D 85.7 (c 1.5,
CHCl3); UV (MeOH) kmax (log e) 258 (3.86) nm; IR (ﬁlm) mmax
3465, 1731, 1718, 1065 cm1; HRESIMS m/z 857.4899 (calcd
for C44H73O16, [M + H]
+, 857.4898).11
6. Conﬂict of interest
None.
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